Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2200)	8/15/1998 1:45:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 4676

I am back. Not very happy about bt sector. :( From 2Q 10Q file: >>The terms of the agreement provide that the Company will receive $5 million in cash payments in 1998. In addition, Isis will receive a 5% equity interest in CpG ImmunoPharmaceuticals, Inc. Based on recent cash purchases of equity securities of CpG ImmunoPharmaceuticals, Inc., the value of Isis' equity position will approximate $1.4 million.<< Also, basic part of the research collaboration with Merck: >>Merck may develop such Research Compounds and Derived Compounds for any purpose subject to any royalty obligations set forth in Article 5. Isis Compounds may be screened by Merck only for activity relative to Hepatitis C polymerase and other anti-viral activity and will be returned to Isis at the end of the Research Program, unless Merck is developing such Isis Compound(s) for any anti-viral indication. << Miljenko